Loading
Life sciences · Journal article
Advanced Healthcare Materials · October 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Despite considerable progress in cancer immunotherapy, the therapeutic efficacy of current cancer therapy continues to be hampered by the immunosuppressive tumor microenvironment (ITME), which is characterized by acidification, hypoxia, elevated H 2 O 2 levels, and aberrant angiogenesis. While transition metal‐based nanomaterials hold great promise for modulating the ITME, their effectiveness is often constrained by insufficient reactive oxygen species (ROS) generation, low immunogenicity, poor immune cell infiltration, and T‐cell exhaustion. To address these issues, we developed a bimetallic Cu/Mn‐doped nanoplatform, CMPTL, which further integrates acid‐dissociable taurine and the angiogenesis inhibitor lenvatinib for malignant solid tumor therapy. This nanoplatform simultaneously triggers violent ROS and cuproptosis, leading to mitochondrial damage and the release of mitochondrial DNA. The subsequent activation of the cGAS‐STING pathway, synergistically enhanced by Mn 2+, initiates robust immune responses. Additionally, taurine helps alleviate T‐cell exhaustion, while lenvatinib promotes tumor vessel normalization, leading to comprehensive remodeling of the TIME. Together, these multimodal mechanisms endow CMPTL with potent antitumor activity, positioning it as a promising candidate for cancer therapy.